drugset / Trial / NCT00198432
Chemoradiotherapy of NSCLC Stage IIIB
Phase 2
Completed
130 enrolled
French Cooperative Thoracic Intergroup
Bristol-Myers Squibb · collabLigue contre le cancer, France · collabPierre Fabre Laboratories · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.
Timeline
- Start
- 2002-03
- Primary completion
- —
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |
| Subject | Vinorelbine | Small molecule | 15 mg/m2 | — |